Dr. Lal PathLabs sees high-teen FY27 growth after Q2 gain

Dr. Lal PathLabs Limited said FY27 revenue growth currently looks likely to be in the high teens after Q2 FY27 revenue rose 19.6% year on year to Rs 874 crore, supported by 9% patient-volume growth and a 9.7% increase in revenue per patient. Management said H1 FY27 performance was slightly ahead of plan.

What is LPL's FY27 revenue outlook?

LPL's current FY27 revenue outlook is growth in the high teens, according to management's November 4, 2026 earnings-call commentary. Management said H1 FY27 revenue of Rs 1,672 crore, up 19.4%, was slightly ahead of its plan. It retained a similar earnings before interest, tax, depreciation and amortisation, or EBITDA, outlook and said the result should be slightly better than last year.

The outlook is a current management assessment rather than a quantified full-year revenue target. Q2 FY27 revenue reached Rs 874 crore, compared with Rs 731 crore in Q2 FY26, producing 19.6% growth. The first-half growth rate of 19.4% was close to the quarterly rate, indicating that the increase was not limited to one quarter.

What drove LPL's 19.6% Q2 revenue growth?

LPL said Q2 FY27 growth was driven by both patient activity and higher revenue per patient. Patient volume increased 9% to 9 million during the quarter, while sample volume increased 13.6% to 28.8 million. Revenue per patient rose to Rs 976 from Rs 889 in Q2 FY26, a 9.7% increase that accompanied the volume expansion.

Management linked patient-volume growth to broad-based demand rather than a single region, while also citing investments made two to three years earlier in laboratories and collection centres. It said the diagnostics industry showed some buoyancy and that LPL's expanding geographic reach contributed. The company described Q2 FY27 as its highest quarterly revenue-growth rate in the last five years.

The Central Government Health Scheme, or CGHS, price increase also provided a temporary revenue tailwind, according to management. Management said this pricing change added about 2% to 3% to revenue growth in Q2 FY27 and would likely remain a factor for another quarter before becoming part of routine organic growth.

How are advanced tests contributing to LPL's growth plan?

LPL is using advanced testing to broaden its diagnostic menu and support test-mix quality. It launched around 140 new tests in H1 FY27 and two first-in-India assays in Q2 FY27, including work across oncogenomics, transplant immunology and rare genetic disorders. Management described medical leadership and clinical tests as the primary engine for test mix and realisation quality.

The company completed the acquisition of S N GeneLab Private Limited in August 2026 to add genomics capability. Management said the acquired business had FY26 revenue of about Rs 60 crore and EBITDA of about Rs 15 crore, although the acquisition was not included for a full Q2 FY27. LPL said S N GeneLab's differentiated portfolio and in-house research and development programme could be deployed across its national network.

Management said specialised tests help LPL differentiate its offering, enter particular client relationships and potentially improve realisations because some tests carry higher prices. It did not describe specialised testing as the sole driver of group growth, saying the current routine and specialised-test mix was appropriate. Management added that routine business can follow when specialised tests provide access to new clients or locations.

Did LPL's profit growth exceed revenue growth in Q2?

LPL's Q2 FY27 EBITDA and profit after tax both grew faster than revenue. EBITDA increased 25.1% to Rs 280 crore from Rs 224 crore, while the EBITDA margin was 32.1%. Profit after tax rose 27.5% to Rs 194 crore from Rs 152 crore, and the profit-after-tax margin was 22.2%.

For H1 FY27, EBITDA increased 26.7% to Rs 528 crore from Rs 416 crore in H1 FY26, with a 31.6% margin. Profit after tax rose 27.3% to Rs 364 crore from Rs 286 crore, with a 21.8% margin. Profit before tax in Q2 FY27 was Rs 261 crore, up 28.1%, and its margin was 29.8%.

LPL reported earnings per share of Rs 11.5 in Q2 FY27 versus Rs 9 in Q2 FY26, and H1 earnings per share of Rs 21.7 versus Rs 17. Net cash stood at Rs 1,746 crore on September 30, 2026. The board also declared a second interim dividend of 50%, or Rs 5 per share.

What operating initiatives is LPL pursuing after H1 FY27?

LPL is extending patient-facing and digital systems while maintaining network expansion. Its redesigned physical report format, with trend charts for common tests and an anti-counterfeit watermark, was reaching more than 80% of patients daily in Q2 FY27. Management also said its rural outreach programme had gained strength across seven launched states, with higher patient numbers during the quarter.

The company established a hybrid-cloud foundation for digital pathology that connects image management, multiple file formats and its laboratory information management system, or LIMS. Management said the platform could support future artificial-intelligence-led services. Separately, LPL said its recent international steps included acquiring Sunshine Diagnostics in Ghana and forming a joint venture in Uzbekistan, which it described as small steps toward a long-term business.

LPL also acquired the remaining 30% stake in Centrapath Labs, making it a wholly owned subsidiary. Management said it remains in search mode for an inorganic opportunity in South India, where the region represented 6% of revenue, while continuing organic work in selected larger urban clusters until it identifies such an opportunity.

Conclusion

LPL's high-teen FY27 revenue-growth outlook follows an H1 FY27 in which revenue increased 19.4% to Rs 1,672 crore and Q2 revenue increased 19.6% to Rs 874 crore. The quarter combined a 9% increase in patients with a 9.7% rise in revenue per patient, while EBITDA and profit after tax grew 25.1% and 27.5%, respectively.

The next results will show whether Q2 FY27's 19.6% revenue growth can be sustained while management pursues its high-teen FY27 outlook. Management has said the CGHS pricing benefit could last another quarter, while the rollout of S N GeneLab's portfolio, around 140 H1 test launches and the seven-state rural programme remain disclosed areas to watch.